Physician profile
Michael J Levitt
NPI 1720074974
$5,793.92
in general payments reported to CMS, 2019-2025
30 companies · $1,130 in 2025
The $1,130 reported for 2025 was more than what a typical Glaucoma Specialist provider received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $854 · 2020: $395 · 2021: $476 · 2022: $980 · 2023: $1,029 · 2024: $930 · 2025: $1,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,089.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,086.06 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $742.64 | 2021-2025 | Acthar |
| Alcon Vision LLC | $525.70 | 2022-2025 | Rocklatan, Luxor, Ngenuity |
| Glaukos Corporation | $411.61 | 2023-2025 | Idosetr, Idose, Radius |
| Allergan, INC. | $384.86 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $339.43 | 2019-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $338.68 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $284.91 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $229.07 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Rxsight INC | $180.10 | 2022-2023 | Rxsight Contact Lens, Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Cartridge |
| Sight Sciences, INC. | $176.05 | 2022-2024 | Omni Surgical System |
| Notal Vision, INC. | $169.76 | 2022 | |
| Ivantis, INC | $146.07 | 2021 | |
| New World Medical,INC. | $141.97 | 2020 | |
| Amgen INC. | $126.42 | 2024-2025 | Tepezza |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $105.40 | 2022-2025 | Iyuzeh |
| Aerie Pharmaceuticals, INC. | $94.33 | 2019-2021 | |
| Oyster Point Pharma, INC. | $34.65 | 2022-2024 | Ryzumvi, Tyrvaya |
| Dompe US, INC. | $33.76 | 2024 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $29.20 | 2024 | Xdemvy |
| Baxter Healthcare | $27.49 | 2025 | Tisseel |
| Eyepoint US, INC. | $24.43 | 2021 | |
| Ocular Therapeutix, INC. | $23.19 | 2024 | Dextenza |
| Harrow Eye, LLC | $22.77 | 2025 | |
| Apellis Pharmaceuticals, INC. | $21.37 | 2025 | Syfovre |
| Johnson & Johnson Surgical Vision, INC. | $20.85 | 2021 | |
| Shire North American Group INC | $19.98 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Eyevance Pharmaceuticals LLC | $19.20 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Levitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.